Quebec filmmaker Denis Villeneuve tapped to direct next James Bond film
Denis Villeneuve is going from 'Dune' to Bond.
AmazonMGM announced Wednesday that Villeneuve will direct the next James Bond movie. The untitled film will be the first since the studio took creative reins of the storied film franchise after decades of control by the Broccoli family.
Producers Amy Pascal and David Heyman had maintained that before the next Bond is cast, they would develop a screenplay and find a director first. Now, they have one of the most respected blockbuster makers in Hollywood who's coming off a pair of widely acclaimed Dune films.
In a statement, Villeneuve said he grew up watching Bond movies.
'I'm a die-hard Bond fan. To me, he's sacred territory,' said Villeneuve. 'I intend to honour the tradition and open the path for many new missions to come. This is a massive responsibility, but also, incredibly exciting for me and a huge honour.'
Since taking creative control of Bond in February, AmazonMGM has worked quickly to get the next movie going. The studio is also trying to win over fans skeptical of the new corporate leadership of 007 and the likelihood of future spinoffs.
A landmark donation from Denis Villeneuve reveals the philanthropy gap for indie cinemas
'James Bond is in the hands of one of today's greatest filmmakers,' said Mike Hopkins, head of Prime Video and Amazon MGM Studios.
With Pascal and Heyman lodged as producers and Villeneuve behind the camera, the next Bond movie will have an enviable brain trust. Villeneuve beat out a field of directors floated for the movie including Edward Berger (Conclave), Paul King (Paddington 2), Edgar Wright (Baby Driver) and Jonathan Nolan, co-creator of Westworld and brother to Christopher Nolan.
'Denis Villeneuve has been in love with James Bond movies since he was a little boy,' said Pascal and Heyman. 'It was always his dream to make this movie, and now it's ours, too.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Montreal Gazette
an hour ago
- Montreal Gazette
Quebec's own Denis Villeneuve will direct the next James Bond film
By The Canadian Press NEW YORK — Denis Villeneuve is going from Dune to Bond. Amazon MGM Studios announced Wednesday that Villeneuve will direct the next James Bond movie. The untitled film will be the first since the studio took creative reins of the storied film franchise after decades of control by the Broccoli family. Producers Amy Pascal and David Heyman had maintained that before the next Bond is cast, they would develop a screenplay and find a director first. Now, they have one of the most respected blockbuster makers in Hollywood, who's coming off a pair of widely acclaimed Dune films. In a statement, the 57-year-old Quebec filmmaker said he grew up watching Bond movies. 'I'm a die-hard Bond fan. To me, he's sacred territory,' said Villeneuve. 'I intend to honor the tradition and open the path for many new missions to come. This is a massive responsibility, but also, incredibly exciting for me and a huge honor.' Since taking creative control of Bond in February, Amazon MGM has worked quickly to get the next movie going. The studio is also trying to win over fans skeptical of the new corporate leadership and the fearful of future spinoffs. 'James Bond is in the hands of one of today's greatest filmmakers,' said Mike Hopkins, head of Prime Video and Amazon MGM Studios. With Pascal and Heyman lodged as producers and Villeneuve behind the camera, the next Bond movie will have an enviable brain trust. Villeneuve beat out a field of directors floated for the movie including Edward Berger (Conclave), Paul King (Paddington 2), Edgar Wright (Baby Driver) and Jonathan Nolan, co-creator of Westworld and brother to Christopher Nolan. 'Denis Villeneuve has been in love with James Bond movies since he was a little boy,' said Pascal and Heyman. 'It was always his dream to make this movie, and now it's ours, too.' No release date has been announced for the next Bond movie. Villeneuve will shoot the third Dune film this summer. If production on Bond began next year, a release sometime in 2027 would be likely. Villenevue's first two 'Dune' films have together surpassed $1 billion in box office worldwide and been nominated for a combined 15 Academy Awards, winning seven. His other films include Blade Runner 2049, Arrival, Sicario, Prisoners, Enemy and Incendies. Amazon bought MGM Studios in 2022 for $8.5 billion, but didn't gain creative control of the studio's most prized asset until this year. Until this film, every Bond director has been handpicked by the Broccolis.
National Post
3 hours ago
- National Post
Pacific Defense Secures Launch for MOSA Space RF Payload
Article content EL SEGUNDO, Calif. — Pacific Defense, the leading provider of Modular Open Systems Approach (MOSA) products, announced it has secured the inaugural launch for its Moonraker MOSA space Radio Frequency (RF) payload on board the K2 Space Gravitas Mission in February 2026. The mission includes a series of multi-orbit Space Situational Awareness (SSA) demonstrations showcasing the payload's mission flexibility. Article content We are taking the MOSA initiative to space with Moonraker. Article content Moonraker is a 3U Open VPX multi-function, RF payload with application software capable of performing a range of RF missions that fundamentally changes the cost, schedule, and deployment concept for responsive space missions. Designed for SSA, Moonraker payload architecture fully supports a range of receive and transmit Electromagnetic Spectrum Operation (EMSO) functions to command the electromagnetic operational environment. Article content 'We're thrilled to take the United States Department of Defense's MOSA initiative to new heights with Moonraker,' said Bryan Terlecky, Vice President of Space Systems at Pacific Defense. 'As global space competition intensifies, there is a pressing need for adaptable, software-driven solutions that can rapidly evolve to counter emerging threats. This mission marks a significant step in our commitment to providing innovative and flexible solutions for space control'. Article content The on-orbit demonstration, being completed under a contract with the Air Force Research Lab/Space Vehicles Directorate (AFRL/RV), is a critical milestone for Pacific Defense's Space MOSA payloads and will inform future operational systems. For more information, please visit Space Systems. Article content About Pacific Defense Article content Article content Article content Article content Contacts Article content Article content
National Post
3 hours ago
- National Post
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
Article content BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Article content Promising new data from pipeline assets in breast, lung, and GI cancer franchises, including CDK4 inhibitor, B7-H4 ADC, and novel PRMT5 inhibitor, will be featured Article content Pipeline is at an exciting inflection point with 20 near-term milestones in the next 18 months Article content SAN CARLOS, Calif. — In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today's investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition. 'At BeOne, our mission is simple yet bold: to create the world's first next-generation oncology company,' said John V. Oyler, Co-Founder, Chairman, and CEO. 'What we will unveil demonstrates our progress towards this goal today, and the promise for tomorrow. From our innovative discovery engine to one of the broadest pipelines in oncology, we are well-positioned to bring transformative medicines to patients worldwide—and to do so with speed, quality, and purpose.' Article content BeOne's integrated, end-to-end R&D model is engineered for efficiency without compromise. The Company's differentiated approach—combining in-house discovery targeting unmet patient needs, parallel early-stage exploration at low incremental cost, and rapid proof-of-concept generation—enables swift progression from bench to clinic. Our in-house manufacturing around the world, including our flagship facility in Hopewell, NJ, means we have a sustainable business model, purpose built with competitive advantages. This rigorous model has fueled a pipeline of more than 40 clinical and commercial-stage assets, making it one of the most productive in the industry. To complement this research engine, BeOne has built a robust global clinical development platform, with more than 170 trials conducted across 40 countries and more than 25,000 patients enrolled to date. Article content In hematologic cancers, the Company's program is driven by its wholly-owned assets including BRUKINSA ® (zanubrutinib), a second-generation covalent BTK inhibitor and the backbone of the hematology franchise, sonrotoclax, a potential best-in-class next-generation BCL2 inhibitor, and BGB-16673, a BTK CDAC. New clinical data from CaDAnCe-101 highlight the promise of BGB-16673, a potential first-in-class BTK degrader, for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL). Meanwhile, early data show the combination of sonrotoclax and BRUKINSA has demonstrated compelling efficacy and the potential to offer a best-in-class fixed-duration treatment in CLL, setting the stage for a possible new standard of care. Article content In solid tumors, the Company is advancing multiple targeted modalities beyond its foundational PD-1 inhibitor TEVIMBRA ® (tislelizumab-jsgr), including CDK4 inhibitor BGB-43395, which has shown clear pharmacodynamic activity and is expected to enter registration-enabling studies for the treatment of breast cancer within the next six to 12 months. Article content Promising new data for the B7-H4 ADC (BG-C9074) point to a potential first-in-class therapeutic option for patients with B7-H4 expressing tumors, including those without selection criteria. Additionally, early data from the novel PRMT5 inhibitor suggest a favorable safety profile and promising efficacy, supporting its potential for differentiation in the competitive lung cancer field. Article content 'Our R&D team is running at full speed,' said Lai Wang, Ph.D., Global Head of R&D. 'With more than 1,200 scientists and more than 3,700 clinical development and medical affairs colleagues dedicated to pushing the boundaries of oncology, we have built the infrastructure, mindset, and capabilities to deliver sustained innovation. The volume of clinical milestones we anticipate over the next few years is extraordinary, and our agility in moving from idea to execution sets us apart.' Article content Speakers at today's event include BeOne's executive leadership team, senior R&D leaders, and distinguished key opinion leaders, offering a multi-faceted view of the Company's scientific strategy and execution momentum. The live webcast begins at 8:30 a.m. U.S. Eastern Time and is available on the investor relations section of BeOne's website, where an archived version will also be accessible. Article content About BeOne Article content BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the future success of BeOne's pipeline assets; BeOne's ability to bring transformative medicines to patients worldwide with both speed and quality; the productivity of BeOne's pipeline; the ability of BeOne's assets to provide a new standard of care; the timing for BGB-43395 to enter registration-enabling studies; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. Article content Article content Article content Article content Article content Contacts Article content
